Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Carducci

Showing results (291-300 of 386) with videos related to

Pageof 39
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2016
A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local TherapyRana R McKay, Amado J Zurita, Lillian Werner, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2020
Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapyLaura A Sena, Hao Wang, Su J Lim ScM, et al.
Plos One|June 30, 2010
Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factorSushant K Kachhap, Nadine Rosmus, Spencer J Collis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 15, 2021
Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trialA A Hamid, H-C Huang, V Wang, et al.
Journal for Immunotherapy of Cancer|October 2, 2020
Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancerClaire F Friedman, Alexandra Snyder Charen, Qin Zhou, et al.
The Prostate|February 26, 2021
Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trialEugene Shenderov, Karim Boudadi, Wei Fu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based ValidationAndres F Correa, Opeyemi Jegede, Naomi B Haas, et al.
European Urology|July 7, 2020
A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide CohortsMark C Markowski, Hao Wang, Rana Sullivan, et al.
Cancer|November 25, 2014
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)Jai N Patel, Chen Jiang, Daniel L Hertz, et al.
JCO Oncology Practice|February 19, 2026
Comparison of Characteristics and Outcomes of Patients With Metastatic Prostate Cancer With and Without Next-Generation Sequencing TestingMadelyn F Klugman, Hua-Ling Tsai, Yasaman Iranmanesh, et al.
Pageof 39

Showing results (291-300 of 386) with videos related to

Sort By:
Pageof 39
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2016
A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local TherapyRana R McKay, Amado J Zurita, Lillian Werner, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2020
Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapyLaura A Sena, Hao Wang, Su J Lim ScM, et al.
Plos One|June 30, 2010
Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factorSushant K Kachhap, Nadine Rosmus, Spencer J Collis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 15, 2021
Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trialA A Hamid, H-C Huang, V Wang, et al.
Journal for Immunotherapy of Cancer|October 2, 2020
Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancerClaire F Friedman, Alexandra Snyder Charen, Qin Zhou, et al.
The Prostate|February 26, 2021
Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trialEugene Shenderov, Karim Boudadi, Wei Fu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2019
Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based ValidationAndres F Correa, Opeyemi Jegede, Naomi B Haas, et al.
European Urology|July 7, 2020
A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide CohortsMark C Markowski, Hao Wang, Rana Sullivan, et al.
Cancer|November 25, 2014
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)Jai N Patel, Chen Jiang, Daniel L Hertz, et al.
JCO Oncology Practice|February 19, 2026
Comparison of Characteristics and Outcomes of Patients With Metastatic Prostate Cancer With and Without Next-Generation Sequencing TestingMadelyn F Klugman, Hua-Ling Tsai, Yasaman Iranmanesh, et al.
Pageof 39